8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report:  May 21, 2014

(Date of earliest event reported)

REVA MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware	000-54192	33-0810505
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

5751 Copley Drive, San Diego, CA	92111
(Address of principal executive offices)	(Zip Code)

(858) 966-3000

(Registrant’s telephone number, including area code)

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

At the Paris Course on Revascularization being held this week in Paris, France, REVA Medical, Inc. (“REVA” or the “Company”) sponsored a symposium entitled, Advancing Bioresorbable Scaffolds through Innovative Biomaterials, where information regarding the Company’s proprietary technology and bioresorbable scaffold programs was presented. The symposium, held May 21, 2014, was chaired by Dr. Alexandre Abizaid, Director of Invasive Cardiology at Institute Dante Pazzanese of Cardiology, in Sao Paulo, Brazil, and featured three separate presentations.

Dr. Marian Rippy, MS, DVM, PhD, of Rippy Pathology Solutions, Inc. in Woodbury, Minnesota, presented data regarding vascular healing following implantation of bioresorbable scaffolds made from REVA’s propriety polymer family. Dr. David Muller, Director, Cardiac Catheterization at St. Vincent’s Hospital, Sydney, Australia, and co-principal investigator for the Company’s RESTORE II clinical trial, presented acute performance data and interim major adverse cardiac event (“MACE”) results through six months in patients implanted with the ReZolve2® bioresorbable scaffold. Dr. Alexandre Abizaid presented information regarding REVA’s high-performance biomaterials that form the foundation for the Company’s Fantom™ scaffold.

The presentation materials delivered at the symposium are attached hereto as Exhibits 99.1 through 99.3. A copy of the materials has also been posted under the Investor Relations section of REVA’s website at www.revamedical.com.

Limitation of Incorporation by Reference

In accordance with General Instruction B.2. of Form 8-K, this information, including Exhibits 99.1 through 99.3, is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD.

Item 9.01   Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No.	Description
99.1	Presentation by Dr. Marian Rippy, MS, DVM, PhD, entitled, Vascular Safety of Bioresorbable Scaffolds Made from Biomaterials Designed for Use In Interventional Cardiology
99.2	Presentation by Dr. David Muller entitled, ReZolve2® Bioresorbable Coronary Scaffold Clinical Program Update
99.3	Presentation by Dr. Alexandre Abizaid entitled, REVA’s Bioresorbable Pipeline Fantom™ Sirolimus-Eluting Bioresorbable Scaffold

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

	REVA Medical, Inc.
Date: May 21, 2014	/s/ Katrina L. Thompson
	Katrina L. Thompson
	Chief Financial Officer
	(principal financial and accounting officer)

3

Index to Exhibits

Exhibit Number	Description of Exhibits
99.1	Presentation by Dr. Marian Rippy, MS, DVM, PhD, entitled, Vascular Safety of Bioresorbable Scaffolds Made from Biomaterials Designed for Use In Interventional Cardiology
99.2	Presentation by Dr. David Muller entitled, ReZolve2® Bioresorbable Coronary Scaffold Clinical Program Update
99.3	Presentation by Dr. Alexandre Abizaid entitled, REVA’s Bioresorbable Pipeline Fantom™ Sirolimus-Eluting Bioresorbable Scaffold

4

EX-99.1

Exhibit 99.1

Vascular Safety of Bioresorbable Scaffolds Made from Biomaterials Designed for Use In Interventional Cardiology Dr. Marian Rippy Rippy Pathology Solutions, Inc. Woodbury, Minnesota

Potential conflicts of interest Speaker's name: Marian Rippy, MS, DVM, PhD, Diplomate, ACVP I do not have any potential conflict of interest  I have the following potential conflicts of interest to report: Consultant: REVA Medical, Inc.

REVA’s Bioresorbable Coronary Scaffolds RESORB Trial 2007 Fantom™ 2014 and beyond ReZolve RESTORE I Trial 2011 ReZolve2 RESTORE II Trial 2013 Each Therapy is Based on the Unique Radiopaque Polycarbonate Polymers 7 Fr. / Bare 6 Fr. / DES 5 Fr. / DES

Key Compounds in REVA’s Polycarbonate Polymers Iodinated Desaminotyrosine (I2DAT) Tyrosine & Analogs Covalently bound iodine enables x-ray visibility of the entire scaffold I2DAT and the tyrosine/analogs are benignly cleared from body

ReZolve I2DAT I2DAT TY ReZolve2 Tyrosine I2DAT I2DAT Tyrosine Ethyl-Ester RESORB PEG PCL I2DAT Tyrosine Ethyl-Ester I2DAT TY PLx I2DAT Fantom™ Polycarbonate Polymer Evolution and Resorption Profile 5 Years 4 Years > 5 Years 3-4 Years Resorption

A Comprehensive Approach to Preclinical Safety Evaluations Study Type Material Safety ISO-10993 Tests of Polymer and Catheter Materials Device Performance and Biocompatibility  Scaffold Implants in Porcine Coronary Arteries Degradation and Resorption Porcine Coronary Arteries Rabbit Subcutaneous Disc Implants Absorption, Distribution, Metabolism and Excretion

ISO-10993 Testing Each Generation of Material Consistently Showed Biocompatibility Polar and nonpolar extracts were tested, where applicable. IS0 - 10993 Test Type of Test Test Conclusion 10993 - 3 Genotoxicity Bacterial Reverse Mutation Study Non - Mutagenic and Non - Geneotoxic Mouse Peripheral Blood Micronucleus Study Non - Geneotoxic In Vitro Chromosomal Aberration in Mammalian Cells Non - Geneotoxic 10993 - 4 Interactions with Blood ASTM Hemolysis study Non - Hemolytic C3a Complement Activation Assay Non - Activator SC5b - 9 Complement Activation Assay Non - Activator ASTM Partial Thromboplastin Time Minimal Activator 10993 - 5 Cytotoxicity ISO Elution Method Non - Cytotoxic 10993 - 10 Sensitization ISO Maximization Sensitization Study Non - S ensitizing 10993 - 10 Irritation Reactivity ISO Intracutaneous Study in Rabbits Non - Irritating 10993 - 11 Systemic Toxicity ISO Systemic Toxicity Study in Mice Non - Toxic

Methodology to Assess Biocompatibility of Treated Coronary Vessels Light Microscopic Parameters % Endothelialization Injury Inflammation Multinucleated Giant Cells Residual Erythrocytes Fibrin Deposits Neovascularization Calcification Medial and Adventitial Necrosis/Hemorrhage (acute) Medial and Adventitial Fibrosis (chronic) Adventitial/Perivascular Inflammation Scanning Electron Microscopic Parameters Endothelialization Coverage Over Struts Between Struts Endothelialization Maturity Over Struts Between Struts Thrombus Inflammatory Cells

Polycarbonate Polymer Scaffolds Heal Safely 1 Month 12 Months 3 Months Demonstrated Biocompatibility and No Adverse Tissue Response to the Iodine-Containing Polymers All H&E images at 12.5x Mag.

Gradual Replacement of Polymer with Artery Tissue * Residual struts 400x Mag. H&E stain 12.5x Mag. at 46 Mos Toluidine blue stain 100x Mag.at 12 Mos * * 2500x Mag.

Degrading and Resorbing Struts (SEM Time Lapse) Non-Degraded >90% Resorbed Highly Degraded & Resorbing Proximal Staple Time ~ 4.5 Years Generalized Polymer Curves 0 - 3 Months 6 -24 Months 36 - 48 Months

Scaffold Resorption Confirmed by X-ray and Micro-CT Non-Degraded 90+% Resorbed Highly Degraded & Resorbing T=0 4.5 Yr 4 Yr

Summary of Polycarbonate Polymer Biocompatibility Feature Outcome Material Biocompatibility ISO-10993 tests demonstrate polymer safety Vascular Healing Biocompatible in porcine arteries throughout material life cycle Degradation & Resorption Safe and predictable Clinical Performance Polycarbonate therapies evaluated in patients are free of any iodine sensitivity

Introducing Fantom™

Fantom™ Breakthroughs Reinforced polymer enables 5Fr compatibility with thinner struts Maintains visibility of the entire scaffold Maintains material safety I2DAT TY PLx I2DAT Fantom™ I2DAT TY PLx I2DAT

Fantom™ Sirolimus-Eluting Bioresorbable Scaffold The next advance in bioresorbable scaffolds Micro-Computed Tomography Images of Scaffolds Still Inside the Porcine Coronary Arteries Thinner Radiopaque Struts Conformable to Vessel Geometry

Fantom™ 3-Month Tissue Response Struts well apposed to the artery wall Stains: Hematoxylin & Eosin (left) and Elastic Trichrome (right) 20X Mag.

Fantom™ 3-Month Tissue Response Stains: Hematoxylin & Eosin (left) and Elastic Trichrome (right) 100X Mag. No adverse reaction and elastic lamina well preserved

I2DAT TY PLx I2DAT Fantom™ Fantom™ Breakdown Products and Resorption Safe Clearance with No Accumulation of the Degradation Products in Vital Organs Radiolabel ADME study shows I2DAT is excreted Naturally occurring in olive oil and excreted Safely Metabolized I2DAT TY PLx I2DAT Resorption 3-4 Years Mechanism Hydrolysis

Summary REVA Material Safety 10 year history of safe vascular use Demonstrated biocompatibility Benign tissue response through full degradation REVA Materials Provide full x-ray visibility Enable reduced strut profile with high flexibility Are easily modifiable for application-specific degradation

Collaborator / Pathology Lab Analysis Fred J Clubb DVM, PhD Director, Cardiovascular Pathology Laboratory

EX-99.2

Exhibit 99.2

ReZolve2® Bioresorbable Coronary Scaffold Clinical Program Update Dr. David Muller St Vincent’s Hospital Sydney, Australia

Potential conflicts of interest Speaker's name: Dr. David Muller I do not have any potential conflict of interest I have the following potential conflicts of interest to report: Institutional grant/research support: REVA Medical, Inc.

ReZolve2® Sirolimus-Eluting Bioresorbable Coronary Scaffold Drug-Eluting (Sirolimus) Radiopaque Strong and Resilient Polymer Unique Slide & Lock Design Desaminotyrosine-derived polycarbonate material that is radiopaque

Novel Approach for Scaffold Performance Proprietary Polymer Desaminotyrosine-derived polycarbonate Biocompatible for safe resorption X-ray visible to aid in scaffold placement Broad degradation tunability Standard handling (not temp sensitive, no refrig.) High Performance Design Traditional inflation (not stepped) Strength to treat real world lesions Expansion to higher diameters without breaking (3.0 mm diameter can go up to 3.9 mm during postdilatation) Conforms to vessel shape ReZolve2 ReZolve2 Metal

Resorption Pathway * Pietrzak WS. Craniofacial Surg 1997;2:92-96 1.0  0.9  0.4 0.8 0.3 0.7 0.2  0.6 0.1 0.5  0  Time ~ 4 Years Generalized Polymer Degradation Curves* Hydrolysis REVA Polymer Molecular Weight Mass Loss I2DAT, Tyrosol, CO2 Excretion H20 ~85% MW degradation by 12 months Absorption and excretion by 3-4 years

Demonstrated Safety ReZolve2 Scaffold Degradation & Healing 0-3 Months 6 -24 Months 36 - 48 Months Non-Degraded Highly Degraded & Resorbing 90+% Resorbed Preclinical studies evaluated in 100s of animals over 11 years Benign degradation process Vasomotion restoration by ~12 - 24 months Absorption and excretion within 48 months

Release Kinetics of Sirolimus Elution profile comparable to commercially successful products 80ug of Sirolimus abluminally coated on 3.0 mm x 18mm scaffold 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 0 20 40 60 80 100 Percent Sirolimus Released Time (Days) ReZolve Cypher Xience

ReZolve2 Clinical Program ReZolve2 Sirolimus-Eluting Bioresorbable Coronary Scaffold Initiated March 2013 Enrolled 112 Patients Primary Endpoint(s): Freedom from ischemic-driven target lesion revascularization at 6 months Quantitative measurements at 9 or 12 months (QCA/IVUS) – Based upon cohort assignment

ReZolve2 Device Specifications 3.0 mm x 18 mm Study Treatment range: 2.75 mm to 3.3 mm Post-dilation up to 3.9 mm 6 Fr. profile 80µg Sirolimus Fully radiopaque Rapid exchange delivery system Balloon expandable No special storage or handling

ReZolve2 Clinical Program Investigators Germany con’t Dr. Volker Schaechinger Dr. Axel Schmermund Dr. Klaus Tiroch New Zealand Dr. Mark Webster Dr. Seif El Jack Dr. John Ormiston Poland Dr. Janusz Kochman Dr. Roman Wojdyla Dr. Dr. Dariusz Dudek Slovenia Dr. Vojko Kanic Australia Dr. David Muller Dr. Darren Walters Dr. Robert Whitbourn Dr. Alan Whelan Dr. Eric Yamen Dr. Sharad Shetty Brazil Dr. Alexandre Abizaid Germany Dr. Norbert Frey Dr. Weber-Albers Dr. Stephen Achenbach Dr. Adnan Kastrati Dr. Holger Nef Dr. Johannes Brachmann Dr. Malte Kelm

ReZolve2 Clinical Program Inclusion/Exclusion Criteria Primary Inclusion Criteria Clinical evidence of myocardial ischemia or positive function test Visually estimated stenosis >50% and <100% Reference vessel diameter 2.75 mm – 3.3 mm (confirmed by QCA) Lesion length ≤ 14mm Primary Exclusion Criteria Myocardial infarctions within 24 hours of the procedure Ejection fraction <30% Target vessel is totally occluded (TIMI 0 or 1) Significant stenosis (>50%) proximal or distal to target lesion Highly calcified lesion

Enrollment Process Step 1 Preliminary Lesion Assessment Preliminary angiographic evaluation Visual assessment of reference vessel diameter Step 2 Lesion Pre-dilation Step 3 Final Lesion Assessment Angiographic evaluation QCA verification of reference vessel diameter Confirm patient eligibility: Enroll Patient Step 4 Implant Scaffold Step 5 Post – Dilation: At physician discretion Step 6 Final Angio, IVUS & OCT evaluation

Case Review 9 Month Protocol Required Follow-up Patient: 001-001

ReZolve2 Scaffold Case Review Case Overview Demographics & Physical Exam Age = 67 Gender = Male Height = 179 cm Weight = 82 kg Heart Rate = 71 bpm Blood Pressure = 124/84 Patient History No current angina History of Hypertension & Hyperlipidemia No prior PCI Non-Smoker No Diabetes LVEF = 60% Summary Positive Function Study Mid-LAD Lesions Reference Vessel Diameter = 3.1mm Lesion Length = 11 mm Baseline Stenosis approx. 65% Enrolled on June 23, 2014 Implanted REVA ReZolve2 Scaffold 9 Mo. Follow-up on: March 25, 2014

BASELINE ANGIOGRAPHY SCAFFOLD DEPLOYMENT INITIAL RESULT (3.0 x 18mm) POST DILATATION (3.5 x15mm) St Vincent’s Hospital Sydney, Australia ReZolve2 Scaffold Case Review

Angiographic Results Baseline Pre-Stenting Baseline Post-Stenting 9 Month Follow-up

9 Month IVUS Result Proximal Scaffold Mid Scaffold Distal Scaffold Scaffold widely patent at 9 months

Case Review 5 Month Unscheduled Follow-up Patient: 003-001 TLR – Site estimated 90% Stenosis

ReZolve2 Scaffold Case Review Patient Demographics Demographics & Physical Exam Age = 61 Gender = Female Height = 150 cm Weight = 51 kg Heart Rate = 63 bpm Blood Pressure = 133/060 Patient History No current angina History of Hypertension & Hyperlipidemia No prior PCI Prior Smoker No Diabetes LVEF = 96% Case Summary Positive Function Study Mid-RCA Lesions Est. 80% diameter stenosis Enrolled on August 16, 2013 Unscheduled follow-up 5 months post procedure on: January 22, 2014 due to recurrent angina

ReZolve2 Scaffold Case Review Baseline Day 0 Images Baseline Assessment RCA Lesion Est. % Dia. Stenosis = 80% Est. RVD = 2.86mm Lesion Length = 14 mm Appears to be shorter TIMI Score = III Pre-dilation NC Quantum 2.75 x 12mm Inflation: 14 atm for 20 sec % dia. stenosis result = 20% TIMI = III No dissection Focal moderate stenosed target lesion

ReZolve2 Scaffold Case Review Baseline Day 0 Images QCA Assessment Distal Reference = 3.1mm Proximal Reference = 3.1mm ARVD = 3.1mm Target Inflation Dia. = 3.3mm Target Inflation Pres. = 12 atm Actual Deployment Data Lot # = BR13372 Serial # = 4124 Inflation Pressure = 12 atm % dia. stenosis result = 0% No dissection Final Result

ReZolve2 Scaffold Case Review Baseline OCT Imaging Proximal Scaffold Mid Scaffold Distal Scaffold

ReZolve2 Scaffold Case Review 5 Month Follow-up Imaging High degree of stenosis throughout scaffold length FUP Angiographic Assessment High degree of diffuse restenosis throughout length of scaffold

ReZolve2 Scaffold Case Review 5 Month Follow-up Imaging Baseline Reference Marks Case Analysis Scaffold was placed more distal than intended. May have contributed to restenosis of scaffold Reference Branch Max Lesion Reference Branch Proximal Edge of Scaffold Post Implant Image

ReZolve2 Clinical Program Preliminary Baseline Characteristics Patient Age (average years) 61 Male 72% Diabetes 23% Current/Former Smoker 68% Hypertension (requiring medication) 82% Hyperlipidemia (requiring medication) 75% Prior PCI 60% Prior CABG 0% Prior MI 41% LVEF 60%

ReZolve2 Clinical Program Target Lesion Location (n=111) LAD 30.6% (34) LCX 30.6% (34) RCA 38.7% (43) ACC/AHA Lesion Class (n=110) Type A 11.8% (13) Type B1 41.8% (46) Type B2 41.8% (46) Type C 4.6% (5) Core Lab Analysis Alexandra Lansky, MD Director, Yale Heart and Vascular Clinical Research

ReZolve2 Clinical Program Baseline Angiographic Characteristics (n=110) Pre-Procedure RVD (mm) 2.90 ± 0.25 Pre-Procedure MLD (mm) 0.94 ± 0.29 Pre-Procedure %DS 67 ± 10 Mean Lesion Length (mm) 11.10 ± 3.07 Final Post- Procedure Final RVD (mm) 2.94 ± 0.26 (n=109) Final In-stent MLD (mm) 2.80 ± 0.24 (n=105) Final In-stent %DS 5 ± 8 (n=104) Acute Recoil (%) -1 ± 8 (n=73) Core Lab Analysis Alexandra Lansky, MD Director, Yale Heart and Vascular Clinical Research

ReZolve2 Clinical Program Acute Procedural Outcomes Technical Success (1) 96% n=112 Acute Procedural Success (2) 98% n=107 Clinical Procedural Success (3) 97% n=107 Defined as successful delivery and deployment of the device. Devices not delivered primarily due to profile. Defined as technical success with residual stenosis <50% with no immediate (in-hospital) MACE. Defined as acute procedure success without the occurrence of MACE through 30 days.

ReZolve2 Clinical Program Interim Results Preliminary Reported MACE Results through 6 Months Follow-up In-Hospital 2 MACE Events 1 TLR 1 post-procedure MI n=107 30-Day Results 1 MACE Events 1 TLR n=106 90-Day Results 0 MACE Events n=105 6-Month Results 3 MACE Events 2 TLRs 1 patient death n=671 Follow up is currently ongoing. Data represents reported events through April 30, 2014.

ReZolve2 Clinical Program Findings Successful acute demonstration of ReZolve2 platform Demonstration of ease-of use features: single step inflation, radiopacity, clinical relevant sizing and standard storage conditions Demonstration of acute performance: 96% delivery success and <2.6% acute recoil 9 & 12 month follow-up ongoing Areas needed further improvement defined Reduction in overall device profile and strut thickness Improvement in mounted scaffold surface smoothness Learnings incorporated into Fantom Program

Thank you

EX-99.3

Exhibit 99.3

 REVA’s Bioresorbable Pipeline Fantom™ Sirolimus-Eluting Bioresorbable Scaffold Dr. Alexandre Abizaid Instituto Dante Pazzanese de Cardiologia Sao Paulo, Brazil

Potential conflicts of interest Speaker's name: Dr. Alexandre Abizaid I do not have any potential conflict of interest  I have the following potential conflicts of interest to report: Institutional grant/research support: REVA Medical, Inc. Consultant: REVA Medical, Inc.

REVA’s Technology History 1998: Company founded around novel steel slide & lock design For minimal recoil 2002: Initiated development of tyrosine-derived polycarbonate polymer Rutgers University Foundation for REVA’s distinctive attributes for polymer scaffolds 2003: 100% effort on bioresorbable scaffolds Evaluated in > 1,000 animals and advanced bench tests Evaluated in > 150 patients beginning in 2007 Proved acute performance, safe resorption, visibility, drug delivery 2014: Introduction of Fantom™

Transition to Fantom ReZolve elegantly designed...but Design required relatively thicker strut segments Up to 230 microns in locking sections A scaffold with -0- recoil is not necessary REVA polymer advancements led to increased design options Physician’s demands for ease of use are increasing More deliverable and lower profile devices Devices that require standard inflation techniques Devices that can be visualized more readily

Foundation of the Fantom Platform Fantom™ Sirolimus-Eluting Bioresorbable Scaffold

REVA polymer family High-performance biomaterials Based on phenyl ring structure Competitive Polymers Polylactide-based Based on Alkane structure REVA Polymers vs. Competitive Polymers Key Structural Polymer Building Blocks Phenyl ring structure provides high strength, radiopaque materials without compromising structural properties

Performance Targets vs. Competitive Polylactide-Based Scaffolds Attribute Fantom Performance Radiopacity +++ Complete X-Ray Visibility Strength + Increase in radial strength Degradation time = Equivalent Crossing profile + Reduced Crossing Profile Inflation performance ++ Single Step Inflation Expansion Range + Meets Clinical Need Shipping and storage + Controlled Shipping Room Temp. Storage

Fantom Bioresorbable Scaffold Radiopacity Fantom’s complete (x-ray) visibility increases confidence during the procedure Precise scaffold placement Complete lesion coverage No geographic miss Confirmation of apposition to vessel wall Reduces need for IVUS & OCT catheter use Saving costs to hospital No permanent metal markers left behind Competitive Scaffolds Visualized Only by Small Permanent Markers (Scaffold Itself is Invisible) Absorb Fantom Xience

Fantom Bioresorbable Scaffold Strength Target & Strut Thickness Increased polymer strength enables reduced strut thickness

Fantom’s Low Crossing Profile Approaches Profiles of Metallic Stents The design goal is to reduce strut thickness without sacrificing scaffold strength REVA’s polymer family has the properties to achieve this goal Decreased strut thickness enables reduced crossing profile Strut Thickness * Metal Drug-Eluting Stent

Effect of Strut Thickness on Crossing Profile A Small Change Has a Big Impact A reduction in strut thickness of only 25 µm achieves 10% decrease in profile and significant improvements in deliverability PLLA Scaffold 1.4 mm (.055”) Fantom <1.27 mm (.050”)

Fantom Bioresorbable Scaffold Single Step Inflation REVAs Advanced Polymer enables single step inflation

Fantom Preclinical Results Angiographic, IVUS and OCT Images thru 3 months Implant One Month Three Month Visibility, conformability and maintenance of vessel patency

Fantom Clinical Plan First Patient Implants anticipated Q4’14 All CE sites fully enrolling by early 2015 Up to 125 patients Over 20 clinical investigational centers BE, BR, DK, FR, DE, NL and PL Primary endpoints MACE and late lumen loss at six months

Fantom Bioresorbable Scaffold Visibility  Strength  Ease-of-Use Superior Scaffold visibility Scaffold strength to treat challenging lesions Improved deliverability with reduced profile Expansion with one smooth and continuous inflation No requirement for “stepped” inflation No procedural time limitations No special storage requirements Human Clinical Evaluation Q4 2014

Thank you